ÂÜÀòÂÒÂ×

Leanne Kelly has a diverse work experience spanning over 20 years. Leanne began their career at KPMG LLP as a Senior Auditor, gaining experience in financial statement audits and SEC filings. Leanne then worked at Luminant Worldwide as an SEC Accountant, where they handled the company's SEC filings and provided guidance on accounting rules and regulations.

Leanne later joined Lamina Ceramics as a Controller before moving on to Genaera Corporation, where they served as the Chief Financial Officer. In this role, they were responsible for all aspects of accounting and finance, including financial reporting, SEC compliance, and business development activities.

After leaving Genaera Corporation, Leanne started their own consulting firm called Kelly Consulting Limited. As the President, they provided financial and accounting assistance to clients undergoing transitions, including start-up, wind-down, and crisis management. Leanne also worked on liquidating trust projects and helped businesses transition to GAAP.

Leanne's next position was at Iroko Pharmaceuticals, LLC, where they served as the Controller. Here, they oversaw financial reporting for multiple entities and currencies, coordinated pre-IPO preparations, and provided support for underwriters and analysts.

Leanne then joined Conventus-Flower Orthopedics as the Senior Vice President of Finance, where they implemented financial record-keeping systems and designed the finance function's operations to complete monthly closes.

Leanne's subsequent role was at Optinose, Inc., where they served as the Controller and Executive Director of Global Financial Reporting. Optinose is a specialty pharmaceutical company focused on products for ear, nose, and throat specialists. Leanne played a pivotal role in the development and commercialization of their first product, XHANCE® nasal spray.

Before their current role, Leanne worked at Vallon Pharmaceuticals as the Chief Financial Officer. Vallon Pharmaceuticals specializes in medications for central nervous system disorders, and Leanne played a key role in their lead investigational product candidate, ADAIR.

Leanne is currently the Chief Financial Officer at GRI Bio, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for inflammatory, fibrotic, and autoimmune diseases. Their role involves overseeing financial operations and contributing to the company's mission to restore the immune system's homeostasis.

Throughout their career, Leanne has demonstrated a strong expertise in financial management, reporting, and regulatory compliance in the pharmaceutical and biotechnology industries.

Leanne Kelly attended Lehigh University from 1994 to 1998, where they earned a Bachelor's degree in Accounting and Finance from the university and a Bachelor of Science (BS) degree in Business and Economics from the College of Business. Leanne also holds the certification of Certified Public Accountant from the Commonwealth of Pennsylvania.